Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

5.945 +0.285 (+5.04%)
Streaming Delayed Price Updated: 3:00 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Savara, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Healthcare Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
SVRA Stock Earnings: Savara Misses EPS for Q2 2024 ↗
SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
SVRA Stock Earnings: Savara Misses EPS for Q1 2024 ↗
SVRA stock results show that Savara missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
From Savara Inc.
Via Business Wire
News headline image
Savara to Host Analyst and Investor Webinar on September 30, 2024
From Savara Inc.
Via Business Wire
News headline image
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
From Savara Inc.
Via Business Wire
News headline image
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? ↗
Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
Via InvestorPlace
News headline image
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
News headline image
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
News headline image
3 Penny Stocks Poised for Major Upside Over the Next 5 Years ↗
These three penny stocks to buy are poised for major upside over the medium-term, for various reasons worth exploring. 
Via InvestorPlace
News headline image
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition ↗
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
News headline image
Savara to Present at the Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.